Pfizer/BioNTech To Supply Additional 100 M Doses of COVID Vaccine to EU
Pfizer and BioNTech, a Mainz, Germany-based immunotherapy company, have announced they will supply an additional 100 million doses of their COVID-19 vaccine to the 27 European Union (EU) member states in 2021.
This announcement is a result of the European Commission’s (EC) decision to exercise its option to purchase an additional 100 million doses under its expanded advanced purchase agreement signed on February 17, 2021. This brings the total number of doses to be delivered to the EU to 600 million.
The vaccine is marketed in the EU under the brand name Comirnaty. Comirnaty will be produced in BioNTech’s and Pfizer’s manufacturing sites in Europe. Comirnaty has been granted conditional marketing authorization by the European Medicines Agency to prevent COVID-19 in people from 16 years of age.